Distinction between HIV-1 and HIV-2 infection using novel synthetic lipopeptide conjugates as antigens in enzyme immunoassays.
A novel immunoassay technique using synthetic lipopeptide (Pam3Cys-Ser) linked to immunodominant peptide domains of HIV-1 and HIV-2 envelope proteins as an antigen adsorbent has been developed. Attachment of peptides to microtiter plates can be considerably improved with this method by employing the hydrophobic properties of lipopeptide. From the sera of 121 HIV-1 infected patients 117 reacted with Pam3Cys-Ser-[HIV-1(598-609)cyclic disulfide]. Five of 5 HIV-2 positive sera were positive with Pam3Cys-Ser-[HIV-2(593-603)cyclic disulfide]. Control sera failed to react with these conjugates.
Böltz
T
T
Institut für Immunobiologie, Universität Freiburg, F.R.G.
Hummel
R P
RP
Tröger
W
W
Rübsamen-Waigmann
H
H
Biesert
L
L
Müller-Lantzsch
N
N
Koch
P
P
Bessler
W
W
Jung
G
G
D000163:Acquired Immunodeficiency Syndrome / Q000175:diagnosis*; D006800:Deltaretrovirus Infections / Q000175:diagnosis*; D004797:Enzyme-Linked Immunosorbent Assay; D000939:Epitopes; D015488:HIV Antigens; D015497:HIV-1; D015498:HIV-2; D006801:Humans; D010456:Peptides, Cyclic; D012191:Retroviridae Proteins / Q000276:immunology; D012984:Software; D014759:Viral Envelope Proteins / Q000276:immunology
D000939:Epitopes; D015488:HIV Antigens; D010456:Peptides, Cyclic; D012191:Retroviridae Proteins; D014759:Viral Envelope Proteins; C058530:palmitoyl(3)-cysteinyl-seryl-(HIV-2(593-603)cyclic disulfide); C058529:palmitoyl(3)-cysteinyl-seryl-(HIV-1(598-609)cyclic disulfide)